Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 4, 2011, Pages 417-421

  Moretti, Vincent M ^a   Crawford, Eileen A ^a   Staddon, Arthur P ^b   Lackman, Richard D ^a   Ogilvie, Christian M ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

chemotherapy; doxorubicin; ifosfamide; malignant peripheral nerve sheath tumor; malignant schwannoma; MPNST; neurofibromatosis

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; RADIOTHERAPY; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79961167340     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e9c08a     Document Type: Article

References (39)

1. Grobmyer SR, Reith JD, Shahlaee A, et al. Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations. J Surg Oncol. 2008;97:340-349. (Pubitemid 351358582)
2. Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors: A clinicopathologic study of 120 cases. Cancer. 1986; 57:2006 -2021. (Pubitemid 16113778)
3. McMenamin ME, Fletcher CD. Expanding the spectrum of malignant change in schwannomas: Epithelioid malignant change, epithelioid malignant peripheral nerve sheath tumor, and epithelioid angiosarcoma: A study of 17 cases. Am J Surg Pathol. 2001;25:13-25. (Pubitemid 32001829)
4. Weiss S, Goldblum JR. Enzinger and Weiss's Soft Tissue Tumors. 4th ed. St Louis, MO: Mosby; 2001.
5. King AA, Debaun MR, Riccardi VM, et al. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet. 2000;93:388-392. (Pubitemid 30622184)
6. Foley KM, Woodruff JM, Ellis FT, et al. Radiation-induced malignant and atypical peripheral nerve sheath tumors. Ann Neurol. 1980;7:311-318. (Pubitemid 10112823)
7. Baehring JM, Betensky RA, Batchelor TT. Malignant peripheral nerve sheath tumor: The clinical spectrum and outcome of treatment. Neurology. 2003;61: 696-698. (Pubitemid 37082610)
8. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62: 1573-1577. (Pubitemid 34407825)
9. Angelov L, Davis A, O'Sullivan B, et al. Neurogenic sarcomas: Experience at the University of Toronto. Neurosurgery. 1998;43:56-64; discussion 64-65.
10. Stark AM, Buhl R, Hugo HH, et al. Malignant peripheral nerve sheath tumours-report of 8 cases and review of the literature. Acta Neurochir (Wien). 2001;143:357-363; discussion 363-364.
11. Wanebo JE, Malik JM, VandenBerg SR, et al. Malignant peripheral nerve sheath tumors: A clinicopathologic study of 28 cases. Cancer. 1993;71:1247-1253. (Pubitemid 23054914)
12. Wong WW, Hirose T, Scheithauer BW, et al. Malignant peripheral nerve sheath tumor: Analysis of treatment outcome. Int J Radiat Oncol Biol Phys. 1998;42:351-360. (Pubitemid 28502782)
13. Okada K, Hasegawa T, Tajino T, et al. Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: A multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol. 2007;14:597-604. (Pubitemid 46175305)
14. Kim DH, Murovic JA, Tiel RL, et al. A series of 397 peripheral neural sheath tumors: 30-year experience at Louisiana State University Health Sciences Center. J Neurosurg. 2005;102:246-255. (Pubitemid 43194074)
15. Kar M, Deo SV, Shukla NK, et al. Malignant peripheral nerve sheath tumors (MPNST)-clinicopathological study and treatment outcome of twenty-four cases. World J Surg Oncol. 2006;4:55.
16. Doorn PF, Molenaar WM, Buter J, et al. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol. 1995;21:78-82.
17. Gachiani J, Kim D, Nelson A, et al. Surgical management of malignant peripheral nerve sheath tumors. Neurosurg Focus. 2007;22:E13.
18. Sordillo PP, Helson L, Hajdu SI, et al. Malignant schwannoma-clinical characteristics, survival, and response to therapy. Cancer. 1981;47:2503-2509. (Pubitemid 11127646)
19. Ramanathan RC, Thomas JM. Malignant peripheral nerve sheath tumours associated with von Recklinghausen's neurofibromatosis. Eur J Surg Oncol. 1999;25:190-193. (Pubitemid 29182463)
20. Anghileri M, Miceli R, Fiore M, et al. Malignant peripheral nerve sheath tumors: Prognostic factors and survival in a series of patients treated at a single institution. Cancer. 2006;107:1065-1074. (Pubitemid 44291156)
21. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23:8422-8430.
22. Cashen DV, Parisien RC, Raskin K, et al. Survival data for patients with malignant schwannoma. Clin Orthop Relat Res. 2004;426:69-73. (Pubitemid 39167110)
23. Steins MB, Serve H, Zuhlsdorf M, et al. Carboplatin/etoposide induces remission of metastasised malignant peripheral nerve tumours (malignant schwannoma) refractory to first-line therapy. Oncol Rep. 2002;9:627-630.
24. Goldman RL, Jones SE, Heusinkveld RS. Combination chemotherapy of metastatic malignant schwannoma with vincristine, adriamycin, cyclophosphamide, and imidazole carboxamide: A case report. Cancer. 1977;39:1955-1958. (Pubitemid 8129027)
25. Hruban RH, Shiu MH, Senie RT, et al. Malignant peripheral nerve sheath tumors of the buttock and lower extremity: A study of 43 cases. Cancer. 1990;66:1253-1265. (Pubitemid 20310668)
26. Gupta AA, Pappo AS. New drugs for the treatment of metastatic or refractory soft tissue sarcomas in children. Future Oncol. 2006;2:675-685. (Pubitemid 44575652)
27. Pappo AS, Lyden E, Breitfeld P, et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. J Clin Oncol. 2007;25:362-369. (Pubitemid 350002984)
28. Imaizumi S, Motoyama T, Ogose A, et al. Characterization and chemosensitivity of two human malignant peripheral nerve sheath tumour cell lines derived from a patient with neurofibromatosis type 1. Virchows Arch. 1998; 433:435-441. (Pubitemid 28522032)
29. Kinebuchi Y, Noguchi W, Igawa Y, et al. Recurrent retroperitoneal malignant nerve sheath tumor associated with neurofibromatosis type 1 responding to carboplatin and etoposide combined chemotherapy. Int J Clin Oncol. 2005; 10:353-356. (Pubitemid 41507211)
30. Das Gupta TK, Brasfield RD. Tumors of peripheral nerve origin: Benign and malignant solitary schwannomas. CA Cancer J Clin. 1970;20:228-233.
31. Vauthey JN, Woodruff JM, Brennan MF. Extremity malignant peripheral nerve sheath tumors (neurogenic sarcomas): A 10-year experience. Ann Surg Oncol. 1995;2:126-131.
32. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol. 1992;19:670-686. (Pubitemid 23004844)
33. Ajithkumar T, Parkinson C, Shamshad F, et al. Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007;19:108-114. (Pubitemid 46172837)
34. Brunello A, Basso U, Rossi E, et al. Ifosfamide-related encephalopathy in elderly patients: Report of five cases and review of the literature. Drugs Aging. 2007;24:967-973. (Pubitemid 350085757)
35. Hanly L, Chen N, Rieder M, et al. Ifosfamide nephrotoxicity in children: A mechanistic base for pharmacological prevention. Expert Opin Drug Saf. 2009;8:155-168.
36. Klastersky J. Side effects of ifosfamide. Oncology. 2003;65(suppl 2):7-10. (Pubitemid 37346723)
37. Carvalho C, Santos RX, Cardoso S, et al. Doxorubicin: The good, the bad, and the ugly effect. Curr Med Chem. 2009;16:3267-3285.
38. Ferreira AL, Matsubara LS, Matsubara BB. Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem. 2008;6:278-281.
39. Injac R, Strukelj B. Recent advances in protection against doxorubicininduced toxicity. Technol Cancer Res Treat. 2008;7:497-516.